Novartis loses latest bid to block generic version of blockbuster heart drug
By Brendan Pierson
Oct 16 (Reuters) -Novartis NOVN.S has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it, though the generic's launch faces other legal roadblocks.
U.S. District Judge Dabney Friedrich in Washington, D.C., in an order made public on Tuesday, said the U.S. Food and Drug Administration did not overstep its authority in approving MSN Pharmaceutical's generic of Entresto, despite a slightly different label and alleged differences between the drugs.
Novartis said in a statement that it disagreed with the ruling and is appealing the decision.
MSN and the FDA did not immediately respond to requests for comment.
Entresto is Switzerland-based Novartis' best-selling drug, earning the company more than $6 billion in revenue last year. MSN's version of Entresto was approved by the U.S. Food and Drug Administration last month and would be the first U.S. generic of the drug.
Novartis has separately sued MSN for patent infringement, and in August lost a bid in that case to block MSN's generic. However, MSN remains barred from launching its generic while Novartis appeals that order.
Novartis sued the FDA in July, shortly after the agency approved MSN's application to sell generic Entresto, alleging that the approval was arbitrary and capricious and violated the federal Food, Drug, and Cosmetic Act (FDCA) in multiple ways.
Novartis said the application should not be approved because MSN's generic label was slightly different from Entresto's.
Entresto was originally approved in 2015 to lower death and hospitalization risk in heart failure patients with reduced ejection fraction, which is the measurement of how much blood the left ventricle of the heart pumps out with each contraction. Following the initial approval, Novartis conducted a clinical trial showing that the drug was effective in patients without reduced ejection fraction, added that indication to the drug's label and obtained patents covering its use in such patients.
To avoid infringing those patents, MSN omitted the indication for patients without reduced ejection fraction from its label. Such label carveouts are known as "skinny labels" and have generally been allowed by courts, including by the D.C. Circuit Court of Appeals in a 1996 decision, Bristol-Myers Squibb v. Shalala.
Novartis, however, said that the federal Food, Drug, and Cosmetic Act prevented MSN from "reverting" to an older label that had been suspended and replaced. It also said the Bristol-Myers ruling was no longer binding precedent after the U.S. Supreme Court's June decision in Loper Bright Enterprises v. Raimondo, which found that courts do not have to defer to federal agencies' interpretations of ambiguous statutes.
Friedrich rejected that argument, finding that the D.C. Circuit's decision had been based on its own reading of the federal Food, Drug, and Cosmetic Act, not deference to the FDA.
Novartis also argued that MSN's generic was not identical to Entresto because it was a simple mixture of the drug's two active ingredients, rather than linking the two molecules together in a crystal structure.
Friedrich said that, under longstanding FDA guidance, "different physical forms do not prevent a demonstration of active ingredient sameness" and that the agency's scientific judgment deserves deference.
The case is Novartis v. Becerra, U.S. District Court for the District of Columbia, No. 1:24-cv-02234.
For Novartis: Susan Cook, Catherine Stetson and Marlan Golden of Hogan Lovells
For the FDA: Gabriel Schonfeld of the U.S. Department of Justice
For MSN: Chad Landmon, Suzanne Bassett, Corey Casey and Kendall Gurule of Polsinelli
Read more:
Novartis loses initial bid to block generic of best-selling heart drug
US Supreme Court curbs federal agency powers, overturning 1984 precedent
(Reporting By Brendan Pierson in New York)
</body></html>
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
